Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00183820
Status:
COMPLETED
Last Update Posted:
2017-07-07
First Post:
2005-09-09
Brief Title:
Study of Gemcitabine Oxaliplatin and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
Sponsor:
University of Southern California
Organization:
University of Southern California
Study Overview
Official Title:
A Phase II Study of Gemcitabine Oxaliplatin and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study for patients with advanced testicular cancer This research study involves treatment with oxaliplatin paclitaxel and gemcitabine which is an investigational chemotherapy combination This study is for patients who have not responded to standard cisplatin-containing chemotherapy or the cancer has returned after such treatment
This research is being done to assess the effectiveness of the proposed combination of medications for this type of cancer
This research is being done to assess the effectiveness of the proposed combination of medications for this type of cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None